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T he lung is the most common site of distant metastases,  accounting for 59-76% of all distant 
metastases from head and neck carcinoma (HNC) [1-3].  
The reported rate of pulmonary metastasis from HNC 
has ranged from 6.0% to 9.1% [4 , 5].  The life expec-
tancy of patients with distant metastasis from HNC has 
been generally short,  and 90% of patients with head and 
neck squamous cell carcinoma (HNSCC) die within 12 
months after the diagnosis of distant metastasis [6 , 7].  
The recent introduction of new drugs such as molecular 
targeting agents (i.e.,  cetuximab) and immune check-
point inhibitors (i.e.,  nivolumab) has resulted in a sta-
tistically significant improvement in the overall survival 
(OS) of patients with recurrent/metastatic HNC [8 , 9],  
and given this situation,  there has been an increase in 
the application of pulmonary metastasectomy [10-18].  
Isolated pulmonary metastases from HNC have long 
been regarded as potentially curable via surgical resec-
tion [4].  At our institution,  our basic strategy for treat-
ing pulmonary metastases from HNC is to surgically 
resect the metastatic lesions even in cases with multiple 
lesions if possible.
We conducted the present study to evaluate and 
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Although the lung is the most common site of distant metastases from head and neck squamous cell carcinoma 
(HNSCC),  the number of reports about the effects of pulmonary metastasectomy for the treatment of lung 
metastasis from HNSCC is limited.  Metachronous pulmonary metastases were detected in 45 HNSCC patients 
at Kumamoto University Hospital from 1998 to 2018.  Twenty-two patients underwent an operative resection 
(Ope group) and 23 underwent chemotherapy (Chemo group).  The 3-year overall survival (OS) rate and 
median OS were evaluated.  The effects of adjuvant chemotherapy after pulmonary metastasectomy and of new 
drugs (cetuximab and nivolumab),  in the chemo group were also assessed.  The 3-year OS rates and median OS 
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versus the patients who underwent surgery alone (p= 0.013).  In the Chemo group,  the 3-year OS rate of the 
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compare the treatment outcomes and prognoses of 
patients with metachronous pulmonary metastases 
from HNSCC after radical treatments with curative 
intent with those of patients who underwent a pulmo-
nary metastasectomy,  patients with unresectable 
lesions,  patients who underwent adjuvant chemother-
apy after pulmonary metastasectomy,  and patients who 
did not undergo a pulmonary metastasectomy.  The 
effectiveness of cetuximab and nivolumab treatments 
was also evaluated.
Patients and Methods
We retrospectively analyzed the cases of 45 HNSCC 
patients in whom metachronous pulmonary metastases 
were detected during the 21-year follow-up period from 
1998 to 2018 after they had undergone radical treat-
ments with curative intent at Kumamoto University 
Hospital (Kumamoto,  Japan).  Patients who also had 
distant metastases at locations other than the lung and 
patients who developed pulmonary metastases before 
the completion of treatment for the primary lesions 
(with the exception of the consecutive oral administra-
tion of S-1) were excluded from the study.
The clinical characteristics of the 45 patients are 
summarized in Table 1.  The patients were 43 men and 
two women,  and the median age at the time of treat-
ment for the primary lesions was 63 years (range 36-82 
years).  The median follow-up period of the surviving 
patients after the detection of pulmonary metastasis 
was 26 months (range 4-146 months).  The locations of 
the primary tumors were the nasal cavity or paranasal 
sinuses (n = 3),  oral cavity (n = 7),  nasopharynx (n = 3),  
oropharynx (n = 7),  hypopharynx (n = 15),  and larynx 
(n = 10).  The primary tumor classifications were stage I 
(n = 1),  stage II (n = 4),  stage III (n = 9),  and stage IV 
(n = 31).  For treatment of the primary tumor,  29 
patients underwent surgical therapy,  15 underwent 
concurrent chemo (bio-) radiotherapy,  and one patient 
underwent radiotherapy only.
The regimens of concurrent chemo (bio-) radiother-
apy for the primary lesions included docetaxel 
(DTX) + cisplatin (CDDP) + fluorouracil (5-FU) (n = 9),  
CDDP + 5-FU (n = 5),  and cetuximab (n = 1).  The sur-
gical therapy regimens included surgery alone (n = 14),  
surgery followed by radiotherapy (n= 10),  and surgery 
followed by chemoradiotherapy (n = 5).
After treatment of the primary HNSCCs,  the patients 
were generally followed up via computed tomography 
(CT) or 18F-fluorodeoxyglucose-positron emission 
tomography (FDG-PET)/CT every 3-6 months during 
the first 2 years and every 6-12 months thereafter.  The 
date of the diagnosis of pulmonary metastases was 
defined as the time when radiologists observed one or 
more suspicious pulmonary lesions on CT or FDG-
PET/CT.  In some patients,  a CT-guided needle biopsy 
was performed to confirm the diagnosis.  Primary lung 
carcinoma was distinguished from pulmonary metasta-
sis based on radiological findings,  pathological diag-
nostic parameters,  and clinical features.
Among the 45 patients,  pulmonary metastasis was 
detected in 15 during the first follow-up year after the 
completion of the treatment for their primary lesions,  
19 during the second year,  and 11 after 2 years (range 
2-76 months).
In all cases,  the treatment policies for metachronous 
pulmonary metastases were determined during cancer 
board meetings with otolaryngologists,  radiologists,  
and general surgeons.  A pulmonary metastasectomy 
was performed in patients whose metastatic lesions 
appeared to have been resected safely and completely.  
Systemic chemotherapy was performed from the begin-
ning in patients for whom surgery could not be per-
formed.  The chemotherapy regimens were also deter-
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Table 1　 Characteristics of HNSCC patients with metachronous 
pulmonary metastasis




Follow up duration (median) 4-146 months (26 months)
Primary lesion
　Nasal cavity/Paranasal sinus 3 (7%)










Treatment of primary lesion
　Operation 29 (64%)
　Chemo (Bio-) radiotherapy 15 (33%)
　Radiotherapy 1 (2%)
HNSCC,  head and neck squamous cell carcinoma.
mined during the aforementioned cancer board 
meetings.  Patients who declined or were not deemed 
suitable for surgical resection or chemotherapy received 
only best supportive care.
The metastatic pulmonary lesion treatment strate-
gies used are shown in Table 2.  Twenty-two patients 
underwent a surgical resection (Ope group) and the 
other 23 underwent chemotherapy (Chemo group).  
The median ages were 62 years (range 38-75 years) in 
the Ope group and 65 years (range 36-82 years) in the 
Chemo group.  The number of pulmonary metastatic 
lesions detected by CT and PET-CT in the Ope group 
was significantly lower than the numbers in the Chemo 
group (p < 0.01).  In the Ope group,  the number of met-
astatic lesions in the resected lung specimens matched 
the number estimated with the use of CT and/or 
PET-CT before the surgeries.  Though most of the 
patients in the Ope group had a single metastatic lesion,  
one patient had 3 lesions and 2 patients each had 2 pul-
monary metastatic lesions.  These multiple metastatic 
lesions were resected respectively with a wedge or seg-
mental resection or lobectomy.
The median sizes of the largest pulmonary meta-
static lesion in each patient were 13 mm (range 
8-27 mm) in the Ope group and 12 mm (range 
6-60 mm) in the Chemo group.  There were no signifi-
cant between-group differences in age,  clinical stage,  or 
the size of largest pulmonary metastatic lesion,  i.e.,  the 
parameters other than the number of pulmonary meta-
static lesions listed in Table 2.
In the Ope group,  some patients received chemo-
therapy as adjuvant therapy after surgical resection,  at 
the discretion of the attending physician.  There were 6 
patients who received chemotherapy (the adjuvant 
group) and 16 who did not (the non-adjuvant group).  
The adjuvant chemotherapy included CDDP + 5-FU +  
cetuximab,  paclitaxel (PTX)+cetuximab,  CDDP+5-FU,  
PTX,  DTX,  and S-1.
In Japan,  cetuximab was approved for treating HNC 
in December 2012,  and nivolumab was approved in 
April 2017.  Accordingly,  the Chemo group included 
16 patients who had received one or both of these drugs 
as of March 2020 (the “recent group”) and 7 patients 
who had not received either of these drugs (the “pre-
ceding group”).
The OS period was defined as the interval from the 
date of the patient’s diagnosis of pulmonary metastasis 
to the date of the patient’s last follow-up or death.  We 
calculated the OS rate by the Kaplan-Meier method.  
The log-rank test was used to compare survival between 
the groups.  Statistical analyses of other parameters were 
performed using the unpaired t-test and χ2-test 
(StatView 5.0 for Windows; SAS Institute,  Cary,  NC,  
USA).  Probability p values < 0.05 were accepted as sig-
nificant.
This study was approved by the Bioethics Committee 
of Kumamoto University (approval no. 2338),  and 
written informed consent to use clinical data obtained 
during the course of their diagnosis and treatment was 
obtained from all patients.  This study was performed in 
accordance with the principles of the Declaration of 
Helsinki.
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Table 2　 Clinical characteristics by treatment modality for metastatic pulmonary lesion of HNSCC patients
Ope group Chemo group
Number of patients 22 23
Age (median) 38-75 years (62 years) 36-82 years (65 years)
Stage
　I 1 (5%) 0
　II 0 4 (17%)
　III 6 (27%) 3 (13%)
　IV 15 (68%) 16 (70%)
Number of pulmonary metastasis＊
　1 18 (82%) 6 (26%)
　2 2 (9%) 3 (13%)
　≧3 1 (5%) 14 (61%)
Size of pulmonary metastasis 8-27 mm (13 mm) 6-60 mm (12 mm)
HNSCC,  head and neck squamous cell carcinoma; Ope,  operation; Chemo,  chemotherapy
＊: There is a significant difference between 2 groups.
Results
The median OS periods and the 3-year OS rates were 
as follows.  All patients: 26 months (range 4-146 months) 
and 53. 1%; Ope group: 31.5 months (range 6-146 
months) and 66.1%; Chemo group: 18 months (range 
4-54 months) and 39.7%.  The OS of the Ope patients 
was significantly better than that of the Chemo patients 
(p = 0.042,  Fig. 1).
In the Ope group,  the median OS periods were 25.5 
months (range 6-64 months) in the adjuvant group 
(n = 6) and 31.5 months (range 7-146 months) in the 
non-adjuvant group (n = 16).  There were no significant 
differences in the 3-year OS rates between the adjuvant 
(83.3%) and non-adjuvant groups (62.5%) (p = 0.386,  
Fig. 2).
Thirteen of the 22 patients in the Ope group showed 
recurred metastases in the lung or other lesions after 
pulmonary metastasectomy (1 of the 6 patients in the 
adjuvant group and 12 of the 16 in the non-adjuvant 
group).  There was a significant difference in the recur-
rence rate between the adjuvant and non-adjuvant 
groups (p = 0.013).
In the Chemo group,  the median OS periods were 
17 months (range 5-38 months) in the patients who 
were not treated with cetuximab or nivolumab (the pre-
ceding group) (n = 7) and 22 months (range 4-54 
months) in the patients who were treated with cetux-
imab or nivolumab or both (the recent group) (n = 16).  
The 3-year OS rate was significantly better in the recent 
group (52.0%) than in the preceding group (14.3%) 
(p = 0.021,  Fig. 3).
Discussion
Pulmonary metastasectomy is a recognized treat-
ment option for a number of different cancers including 
colorectal cancers,  sarcoma,  melanoma,  and renal cell 
carcinoma [19].  In cases of HNC,  the number of 
reports on the usefulness of pulmonary metastasectomy 
has been increasing [10-18].  The reported 5-year OS 
rate after pulmonary metastasectomy has ranged from 
35.7% to 59.4% for all histopathological carcinomas 
[10-15] and from 19.4% to 28.6% for squamous cell car-
cinomas (Table 3) [11 , 16-18].  Although the follow-up 
period in our present patient series was relatively short,  
the 3-year OS rate after pulmonary metastasectomy was 
excellent (66.1%).  This result suggests that pulmonary 
metastasectomy should be considered as a treatment 
option in appropriate cases.
The usefulness of adjuvant chemotherapy after pul-
monary metastasectomy in cases of colorectal carci-
noma has been described [20 , 21].  With regard to 
HNC,  only one published study investigated the effects 
of adjuvant chemotherapy after pulmonary metastasec-
tomy [14].  In that study,  the 5-year OS rate in the adju-
vant chemotherapy group (n = 20) did not differ signifi-
cantly from that in the surgery-alone group (n = 38).  In 
34 Miyamaru et al. Acta Med.  Okayama　Vol.  75,  No.  1
Number of patients OS period (median) 3-year OS rate
All patients 45 4-146 months (26 months) 53.1%
Ope group 22 6-146 months (31.5 months) 66.1%
Chemo group 23 4-54 months (18 months) 39.7%






























(Ope group vs. Chemo group)
Fig. 1　 Overall survival (OS) curves for all patients,  those in the Ope (operation) group,  and those in the Chemo (chemotherapy) group.
the present investigation,  although there was no signif-
icant difference in the 3-year OS rate between the adju-
vant and non-adjuvant groups,  the recurrence rate was 
significantly better in the adjuvant group than in the 
non-adjuvant group.  These results suggest that adjuvant 
chemotherapy after pulmonary metastasectomy may 
prevent additional metastases.  Because the number of 
patients in the present study was relatively small (n= 45),  
further studies including more patients are necessary.
The OS rate of the Chemo group was significantly 
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Number of patients OS period (median) 3-year OS rate
Preceding group 7 5-38 months (17 months) 14.3%
Recent group 16 4-54 months (22 months) 52.0%
OS, overall survival.
Preceding group: patients who did not use cetuximab or nivolumab;





























Fig. 3　 OA curves for the preceding and recent subgroups of the Chemo group.  Preceding group: patients who were not treated with 


























Number of patients OS period (median) 3-year OS rate
Adjuvant group 6 6-64 months (25.5 months) 83.3%
Non-adjuvant group 16 7-146 months (31.5 months) 62.5%
OS, overall survival. 
Adjuvant group: patients who received chemotherapy after pulmonary metastasectomy; 




Fig. 2　 OS curves for the adjuvant and non-adjuvant subgroups of the Ope group.  Adjuvant group: patients treated with chemotherapy 
after pulmonary metastasectomy; Non-adjuvant group: patients who were not treated with chemotherapy after pulmonary metastasectomy.
worse than that of the Ope group in this study.  
Although this result may be due mainly to the large 
number of lung metastatic lesions in the Chemo group,  
the existence of distant metastatic lesions in sites other 
than the lung and the general condition of the patient 
should also be considered in decisions regarding 
whether surgery should be performed.  Patient selection 
bias in addition to the number of metastatic lesions in 
the lung might thus have affected the difference in the 
OS rate that we observed between the present Ope and 
Chemo groups.
With regard to HNSCC recurrence or metastasis,  
median OS periods ranging from 7.4 to 10.1 months 
have been reported in patients who underwent chemo-
therapy after the detection of recurrence [8].  In the 
present study the median OS period after the detection 
of pulmonary metastasis in the Chemo group was 18 
months.  This relatively good OS may have been due to 
the use of cetuximab or nivolumab or both in 16 of the 
23 Chemo group cases.  In the patients treated with 
cetuximab or nivolumab or both,  the median OS 
period after the detection of pulmonary metastasis was 
22 months.  In addition,  the 3-year OS rate in the 
recent group was significantly better than that in the 
preceding group.  These results indicate that cetuximab 
and nivolumab were effective in cases of pulmonary 
metastasis of HNSCC.
A study limitation was the difficulty in distinguish-
ing pulmonary metastases of HNSCC from primary 
lung squamous cell carcinoma,  which was due to simi-
larities in their histopathological and radiographical 
presentations and a lack of useful markers.  Many 
patients with HNSCC have a history of heavy smoking,  
which is also a risk factor for lung cancer.  One report 
revealed that the incidence of lung cancer in HNC 
patients was 3-6 times higher than that in the normal 
population [22].
Recent studies indicate that the expression of epi-
dermal growth factor receptor mutation in squamous 
cell carcinoma is 90% in HNC patients,  whereas in lung 
cancer patients,  it is only 0-13%; this expression may 
therefore be a useful marker for distinguishing between 
HNC and lung cancer [8 , 23 , 24].  In addition,  analyses 
of the loss of heterozygosity [25] and immunostaining 
patterns [26] have been used to distinguish between 
pulmonary metastasis from HNC and primary lung 
cancer.  The prognoses after the pulmonary resection of 
both metastasis from HNC and primary lung cancer 
were studied [27]; the median OS periods after the 
resection of molecularly defined primary lung cancer 
(23.1 months) and pulmonary metastasis from HNSCC 
(25.1 months) did not differ significantly.  That result 
suggests that differences between pulmonary metastasis 
of HNSCC and primary lung squamous cell carcinoma 
were unlikely to have influenced our present findings.
In conclusion,  the surgical resection of metachro-
nous pulmonary metastases from HNSCC is a reliable 
treatment option in appropriate patients.  Adjuvant 
chemotherapy after pulmonary metastasectomy may be 
preferable for preventing recurrences.  Cetuximab and 
nivolumab may have improved the overall survival of 
the patients with metachronous pulmonary metastases 
from HNSCC in this study.  It may be necessary to 
determine the optimal combination and order of 
administration of ‘old’ and ‘new’ drugs for the treatment 
of metachronous pulmonary metastases from HNSCC.
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